Jubilant Pharmova subsidiary and contract manufacturer Jubilant HollisterStier LLC (JHS) has launched a $132 million new sterile fill and finish line at its Spokane manufacturing facility in Washington, U.S..

It is the third such line of JHS, which specialises in sterile injectables and caters to leading global innovator pharma companies. The subsidiary is on track to double its total sterile injectable manufacturing capacity at the facility in the U.S., once the upcoming fourth line is commissioned, the parent company said on Friday (October 10, 2025).

“With third line operational and fourth on the horizon, we are not just doubling our capacity, we’re building a future that will create hundreds of new jobs, strengthen the U.S. pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world,” CEO — CDMO Sterile Injectables Chris Preti said in a release.

Large innovator pharma companies are looking for high quality, US manufacturing facilities in the wake of new tariffs imposed by the U.S. government. In this backdrop, the company is witnessing a very strong traction in requests for proposals (RFPs) for the new line. “We expect to reach the full utilisation for the new line in the next three years,” he said, seeking to reiterate how the expansion reflects the company’s deep-rooted commitment, to continued growth, technological excellence and the community at Spokane.

The investment reinforces JHS’ leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the company is contributing to US national health security and helping to reduce reliance on offshore supply chains — delivering a more resilient and agile pharmaceutical manufacturing ecosystem, Jubilant Pharmova (Jubilant Life Sciences) said. The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new Line. The new line, equipped with advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision, is part of a multi-phase expansion strategy. It brings an additional 50% capacity at the Spokane manufacturing facility.